Managing Methotrexate Intolerance in Rheumatoid Arthritis: The Role of Oral-to-Subcutaneous Switching

Clicks: 2
ID: 325529
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #30 of 36 articles by views in modern rheumatology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Methotrexate (MTX) remains the anchor drug in the management of rheumatoid arthritis (RA). However, its clinical use is frequently limited by intolerance, leading to dose reduction or discontinuation. In addition, oral MTX exhibits pharmacokinetic limitations, including dose-dependent absorption and reduced bioavailability at higher doses, which may compromise therapeutic efficacy. Subcutaneous (SC) MTX has emerged as a strategy to overcome these limitations by providing more consistent bioavailability and potentially improved tolerability. Evidence suggests that switching from oral-to-SC MTX may improve gastrointestinal (GI) intolerance and support treatment persistence, whereas evidence for improved disease control or reduction of serious MTX-related toxicity remains limited. Recent Japanese studies suggest the potential utility of this approach at MTX doses commonly used in Japan, although evidence for the superiority of SC MTX over oral MTX in low-dose settings remains limited. This narrative review summarizes current evidence on MTX intolerance and oral-to-SC route switching in RA, with a focus on practical strategies for treatment optimization. Overall, oral-to-SC MTX switching may represent an important option to improve GI intolerance and support treatment persistence in patients with RA.
Reference Key
openalex_W7203775841 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Shin‐ichiro Ohmura
Journal modern rheumatology
Year 2026
DOI
10.1093/mr/roag070
URL
https://doi.org/10.1093/mr/roag070
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.